PMID- 33501883
OWN - NLM
STAT- MEDLINE
DCOM- 20210906
LR  - 20240403
IS  - 1521-0464 (Electronic)
IS  - 1071-7544 (Print)
IS  - 1071-7544 (Linking)
VI  - 28
IP  - 1
DP  - 2021 Dec
TI  - Stimuli-responsive drug delivery systems for head and neck cancer therapy.
PG  - 272-284
LID - 10.1080/10717544.2021.1876182 [doi]
AB  - Head and neck cancer (HNC) is among the most common malignancy that has a 
      profound impact on human health and life quality. The treatment for HNC, 
      especially for the advanced cancer is stage-dependent and in need of combined 
      therapies. Various forms of adjuvant treatments such as chemotherapy, 
      phototherapy, hyperthermia, gene therapy have been included in the HNC therapy. 
      However, there are still restrictions with traditional administration such as 
      limited in situ therapeutic effect, systemic toxicity, drug resistance, etc. In 
      recent years, stimuli-responsive drug delivery systems (DDSs) have attracted the 
      great attention in HNC therapy. These intelligent DDSs could respond to unique 
      tumor microenvironment, external triggers or dual/multi stimulus with more 
      specific drug delivery and release, leading to enhanced treatment efficiency and 
      less reduced side effects. In this article, recent studies on stimuli-responsive 
      DDSs for HNC therapy were summarized, which could respond to endogenous and 
      exogenous triggers including pH, matrix metalloproteinases (MMPs), reactive 
      oxygen species (ROS), redox condition, light, magnetic field and multi stimuli. 
      Their therapeutic remarks, current limits and future prospect for these 
      intelligent DDSs were discussed. Furthermore, multifunctional stimuli-responsive 
      DDSs have also been reviewed. With the modification of drug carriers or 
      co-loading with therapeutic agents. Those intelligent DDSs showed more 
      biofunctions such as combined therapeutic effects or integration of diagnosis and 
      treatment for HNC. It is believed that stimuli-responsive drug delivery systems 
      showed great potential for future clinic translation and application for the 
      treatment of HNC.
FAU - Liang, Jingou
AU  - Liang J
AD  - State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral 
      Diseases, West China School of Stomatology, Sichuan University, Chengdu, China.
AD  - Department of Pediatric Dentistry, West China School of Stomatology, Sichuan 
      University, Chengdu, China.
FAU - Yang, Bina
AU  - Yang B
AD  - State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral 
      Diseases, West China School of Stomatology, Sichuan University, Chengdu, China.
AD  - Department of Cariology and Endodontics, West China School of Stomatology, 
      Sichuan University, Chengdu, China.
FAU - Zhou, Xuedong
AU  - Zhou X
AD  - State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral 
      Diseases, West China School of Stomatology, Sichuan University, Chengdu, China.
AD  - Department of Cariology and Endodontics, West China School of Stomatology, 
      Sichuan University, Chengdu, China.
FAU - Han, Qi
AU  - Han Q
AD  - State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral 
      Diseases, West China School of Stomatology, Sichuan University, Chengdu, China.
FAU - Zou, Jing
AU  - Zou J
AD  - State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral 
      Diseases, West China School of Stomatology, Sichuan University, Chengdu, China.
AD  - Department of Pediatric Dentistry, West China School of Stomatology, Sichuan 
      University, Chengdu, China.
FAU - Cheng, Lei
AU  - Cheng L
AD  - State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral 
      Diseases, West China School of Stomatology, Sichuan University, Chengdu, China.
AD  - Department of Cariology and Endodontics, West China School of Stomatology, 
      Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Drug Deliv
JT  - Drug delivery
JID - 9417471
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biocompatible Materials)
RN  - 0 (Drug Carriers)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Smart Materials)
RN  - 0 (Stimuli Responsive Polymers)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage
MH  - Biocompatible Materials
MH  - Drug Carriers
MH  - *Drug Delivery Systems
MH  - Head and Neck Neoplasms/*drug therapy
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Light
MH  - Magnetic Fields
MH  - Matrix Metalloproteinases/metabolism
MH  - Oxidation-Reduction
MH  - Reactive Oxygen Species/metabolism
MH  - Smart Materials
MH  - Squamous Cell Carcinoma of Head and Neck/*drug therapy
MH  - *Stimuli Responsive Polymers
MH  - Tumor Microenvironment
PMC - PMC7850355
OTO - NOTNLM
OT  - Stimuli-responsive drug delivery systems
OT  - anticancer therapy
OT  - head and neck cancer
OT  - intelligent biomaterials
OT  - tumor microenvironment
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2021/01/28 06:00
MHDA- 2021/09/07 06:00
PMCR- 2021/01/27
CRDT- 2021/01/27 08:37
PHST- 2021/01/27 08:37 [entrez]
PHST- 2021/01/28 06:00 [pubmed]
PHST- 2021/09/07 06:00 [medline]
PHST- 2021/01/27 00:00 [pmc-release]
AID - 1876182 [pii]
AID - 10.1080/10717544.2021.1876182 [doi]
PST - ppublish
SO  - Drug Deliv. 2021 Dec;28(1):272-284. doi: 10.1080/10717544.2021.1876182.